Pediatric Hodgkin Lymphoma Differential Diagnoses

1. Arya LS, Dinand V. Current strategies in the treatment of childhood Hodgkins disease. Indian Pediatr. 2005 Nov. 42(11):1115-28. [QxMD MEDLINE Link].

2. Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF. Social class and risk of Hodgkin's disease in young-adult women in 1988-94. Int J Cancer. 2002 Mar 1. 98(1):110-7. [QxMD MEDLINE Link].

3. Ng AK, Mauch PM. Late effects of Hodgkin's disease and its treatment. Cancer J. 2009 Mar-Apr. 15(2):164-8. [QxMD MEDLINE Link].

4. Lymphoma - Hodgkin: Statistics. Cancer.Net. Available at https://www.cancer.net/cancer-types/lymphoma-hodgkin-childhood/statistics. January 2021; Accessed: June 2, 2021.

5. Robertson VL, Anderson CS, Keller FG, Halkar R, Goodman M, Marcus RB, et al. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2011 Jun 1. 80(2):324-32. [QxMD MEDLINE Link].

6. National Cancer Institute. SEER stat fact sheets: Hodgkin lymphoma. Available at https://seer.cancer.gov/statfacts/html/hodg.html. Accessed: June 2, 2021.

7. Schwartz CL, Kaplan J, Chen L, Hutchison RE, Kelly KM, Wolden SL. Albumin: A Predictor of EFS in MC Hodgkin Lymphoma. Pediatrirc Blood and Cancer. 2012. 59:978.

8. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009 Jul. 146(2):171-9. [QxMD MEDLINE Link].

9. Harris NL. Hodgkin's disease: classification and differential diagnosis. Mod Pathol. 1999 Feb. 12(2):159-75. [QxMD MEDLINE Link].

10. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. 4th ed. Lyon, France: IARC Press; 2008. Vol 2:

11. Küppers R, Yahalom J, Josting A. Advances in biology, diagnostics, and treatment of Hodgkin's disease. Biol Blood Marrow Transplant. 2006 Jan. 12(1 Suppl 1):66-76. [QxMD MEDLINE Link].

12. Castellino AM. New ILROG guidelines for pediatric Hodgkin’s lymphoma. Medscape Medical News. Oncology. WebMD Inc. Available at http://www.medscape.com/viewarticle/841252. Accessed: April 30, 2015.

13. Hodgson DC, Dieckmann K, Terezakis S, Constine L. Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Pract Radiat Oncol. 2015 Mar-Apr. 5(2):85-92. [QxMD MEDLINE Link].

14. Al-Rahawan MM, A de Alarcón PA. Gemcitabine and vinorelbine therapy for patients with Hodgkin lymphoma. Pediatric Health. 2009 Dec. 3(6):525-32.

15. Shankar A, Visaduraki M, Hayward J, Morland B, McCarthy K, Hewitt M. Clinical outcome in children and adolescents with Hodgkin lymphoma after treatment with chemotherapy alone - The results of the United Kingdom HD3 national cohort trial. Eur J Cancer. 2011 Jun 22. [QxMD MEDLINE Link].

16. Ng AK, Mauch PM. Late effects of Hodgkin's disease and its treatment. Cancer J. 2009 Mar-Apr. 15(2):164-8. [QxMD MEDLINE Link].

17. Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol. 2009 Mar 20. 27(9):1456-61. [QxMD MEDLINE Link]. [Full Text].

18. Sandlund JT, Pui CH, Mahmoud H, et al. Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. Ann Oncol. 2011 Feb. 22(2):468-71. [QxMD MEDLINE Link]. [Full Text].

19. Moskowitz CH, et al. Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. Presented at the American Society of Hematology, 58th Annual Meeting and Exposition. San Diego, CA. 2016 Dec 3-6. [Full Text].

20. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993 Apr 24. 341(8852):1051-4. [QxMD MEDLINE Link].

21. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002 Jun 15. 359(9323):2065-71. [QxMD MEDLINE Link].

22. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 Nov 4. 363(19):1812-21. [QxMD MEDLINE Link].

23. Pajonk F, Pajonk K, McBride WH. Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys. 2000 Jul 1. 47(4):1025-32. [QxMD MEDLINE Link].

24. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood. 2006 Feb 15. 107(4):1731-2. [QxMD MEDLINE Link].

25. LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res. 2006 Sep 1. 12(17):5231-41. [QxMD MEDLINE Link].

26. Johnston PB, Colgan JP et al. Promising results for patients with relapsed or refractory Hodgkin lymphoma related with the oral MTOR inhibitor everolimus (RAD001). Presented at the Seventh International Symposium on Hodgking Lymphoma, Cologne Abstract 099. 2007.

27. Cheson BD, Bartlett NL. Hodgkin Lymphoma: New Drug Breakthroughs. Medscape News Today. Available at http://www.medscape.com/viewarticle/733776. Accessed: September 18, 2011.

28. Böll B, Bredenfeld H, Görgen H, Halbsguth T, Eich HT, Soekler M, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011 Dec 8. 118(24):6292-8. [QxMD MEDLINE Link].

29. Cindy Schwarts, Louis onstine, Suzzane Wolden, Frank G. Keller, Kara M. Keller and Debra I. Friedman. The Childhood Hodgkin Internatinal Prognostic Score (CHIPS) for Predicting Event Free Survival in Pediatric and Adolescent Hodgkin Lymphoma. Blood [serial online]. December 2, 2011. [Full Text].

30. Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leuk Lymphoma. 2011 Sep. 52(9):1641-54. [QxMD MEDLINE Link].

31. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009 Jan. 9(1):15-27. [QxMD MEDLINE Link].

32. Percy CL, Smith MA, Linet M, et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995: Lymphomas and Reticuloendothelial Neoplasms [Surveillance, Epidemiology, and End Results Web site]. November 5, 1999. National Cancer Institute: Surveillance Epidemiology and End Results. Available at http://www.seer.cancer.gov.

33. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood. 2005 Jun 15. 105(12):4553-60. [QxMD MEDLINE Link].

34. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19. 117(20):5314-20. [QxMD MEDLINE Link]. [Full Text].

Pedro A de Alarcon, MD William H Albers Professor and Chair, Department of Pediatrics, University of Illinois College of Medicine at Peoria

Pedro A de Alarcon, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, American Society of Pediatric Hematology/Oncology, International Society of Hematology, International Society on Thrombosis and Haemostasis, Medical Society of the State of New York, New York Academy of Sciences, Society for Pediatric Research, Southern Society for Pediatric Research, Children's Oncology Group, Eastern Society for Pediatric Research, National Hemophilia Foundation, International Society for Experimental Hematology, Virginia Chapter of The American Academy of Pediatrics, Virginia Pediatric Society, American Federation for Clinical Research

Disclosure: Nothing to disclose.

Mohamad M Al-Rahawan, MD, MPH Associate Professor of Clinical Pediatrics, Division Chief of Pediatric Hematology/Oncology, Department of Pediatrics, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Attending Pediatric Hematologist/Oncologist, Covenant Women's and Children's Hospital

Mohamad M Al-Rahawan, MD, MPH is a member of the following medical societies: American Society of Hematology, American Society of Pediatric Hematology/Oncology, Children's Oncology Group

Disclosure: Nothing to disclose.

Monika Metzger, MD, MSc Assistant Professor, University of Tennessee School of Medicine; Assistant Member, Department of Oncology, Division of Leukemia and Lymphoma, St Jude Children's Research Hospital

Monika Metzger, MD, MSc is a member of the following medical societies: Children's Oncology Group

Disclosure: Nothing to disclose.

Karen S Fernandez, MD Assistant Professor of Pediatrics, Jim and Katie Owens Professorship in Pediatric Hematology Oncology, Division of Hematology/Oncology, University of Illinois College of Medicine at Peoria; Pediatric Oncologist, Children's Hospital of Illinois, OSF Medical Center

Karen S Fernandez, MD is a member of the following medical societies: American Academy of Hospice and Palliative Medicine, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Connective Tissue Oncology Society, Children's Oncology Group, American Society of Clinical Oncology, Hemophilia and Thrombosis Research Society, National Hispanic Medical Association, Histiocyte Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Steven K Bergstrom, MD Department of Pediatrics, Division of Hematology-Oncology, Kaiser Permanente Medical Center of Oakland

Steven K Bergstrom, MD is a member of the following medical societies: Alpha Omega Alpha, Children's Oncology Group, American Society of Clinical Oncology, International Society for Experimental Hematology, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Vikramjit S Kanwar, MBBS, MBA, MRCP(UK) Professor Emeritus of Pediatrics, Albany Medical College; Chief of Pediatric Oncology, Homi Bhabha Cancer Hospital, Varanasi, India

Vikramjit S Kanwar, MBBS, MBA, MRCP(UK) is a member of the following medical societies: Children's Oncology Group, Indian Academy of Pediatrics, International Society of Pediatric Oncology

Disclosure: Nothing to disclose.

Kathleen M Sakamoto, MD, PhD Shelagh Galligan Professor, Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine

Kathleen M Sakamoto, MD, PhD is a member of the following medical societies: American Association for Cancer Research, American Society of Hematology, American Society of Pediatric Hematology/Oncology, International Society for Experimental Hematology, Society for Pediatric Research, Western Society for Pediatric Research

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article